✦ LIBER ✦

Clinical experience on the role and significance of selegiline in the treatment of Parkinson's disease

Book ID: 114782843
Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 514 KB
Volume: 80
Category: Article
ISSN: 0001-6314
DOI: 10.1111/j.1600-0404.1989.tb01803.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Selegiline in the treatment of Parkinson

Selegiline in the treatment of Parkinson's disease — long term experience

✍ M. D. Yahr; T. S. Elizan; D. Moros 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB

Selegiline in the treatment of Parkinson

Selegiline in the treatment of Parkinson's disease

✍ Heinonen E H; Rinne U K 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 708 KB

Clinical evaluation of deprenyl (selegil

Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease

✍ E. CSANDA; M. TÁRCZY 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

Deprenyl (selegiline) in the treatment o

Deprenyl (selegiline) in the treatment of Parkinson's disease

✍ W. BIRKMAYER 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

Deprenyl (selegiline) in the treatment o

Deprenyl (selegiline) in the treatment of Parkinson's disease

✍ U. K. RINNE 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB

Selegiline ? An overview of its role in

Selegiline ? An overview of its role in the treatment of Parkinson's disease

✍ Wessel, K. ;Szelenyi, I. 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 389 KB

Selegiline (10 mg per day) selectively inhibits monoamine oxidase type B and thus thwarts the metabolism of dopamine by this enzyme. Selegiline has been used in the therapy of Parkinson's disease since 1986. It enhances the efficacy of levodopa, allows a reduction of the levodopa dose, and improves